The FDA asked Bristol-Myers Squibb and Sanofi-Aventis, the manufacturers of Plavix, to study whether genetic factors or proton pump inhibitors -- a class of medicines used to treat acid reflux or heartburn -- interfere with efficacy of the blood thinner. The agency said it may need "several months" to arrive at a conclusion, but it intends to quickly evaluate the research.

Related Summaries